Results 81 to 90 of about 458,313 (258)

Case Report of Acute Central Airway Obstruction Induced by Anti‐PD‐1 Sintilimab: Clinical Presentation and Review

open access: yesClinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Immune checkpoint inhibitors (ICIs), such as sintilimab, have revolutionized non‐small cell lung cancer (NSCLC) treatment but can trigger immune‐related adverse events (irAEs). While pneumonitis is well documented, central airway obstruction (CAO) due to immune‐mediated necrosis is an extremely rare and life‐threatening phenotype that poses ...
Ting Ouyang   +3 more
wiley   +1 more source

Mapping VEXAS‐associated and rare UBA1 variants in the United Kingdom: Insights from patient cohorts and the general population

open access: yesBritish Journal of Haematology, Volume 208, Issue 1, Page 116-128, January 2026.
VEXAS syndrome is a late‐onset inflammatory disorder with rheumatological and haematological features. Epidemiological studies of VEXAS syndrome so far have been limited. Analysis of various UK cohorts estimates the incidence of VEXAS to be 1.51/100 000, or 171 new cases in the population of men over the age of 50 who are being investigated for myeloid
Ana Martinez Rodriguez   +15 more
wiley   +1 more source

Management of an extracranial internal carotid artery aneurysm secondary to relapsing polychondritis

open access: yesJournal of Vascular Surgery Cases and Innovative Techniques, 2020
Extracranial internal carotid artery (EICA) aneurysms make up 1% of peripheral aneurysms and less than 1% of patients who have relapsing polychondritis develop aneurysms.
Kush J. Sharma, MD   +3 more
doaj   +1 more source

Biodegradable Stents—A New Option for Benign Central Airway Stenosis

open access: yesRespirology, Volume 30, Issue 12, Page 1176-1183, December 2025.
Airway stenting using conventional stents for benign central airway stenosis has considerable complication rates as well as technical difficulties while placing and removing. Polydioxanone biodegradable stents serve as a feasible alternative for individuals requiring temporary airway support.
Oğuz Karcıoğlu   +6 more
wiley   +1 more source

Clinical associations of serum antiendothelial cell antibodies in patients with sudden sensorineural hearing loss [PDF]

open access: yes, 2003
Objectives/Hypothesis: The role of antiendothelial cell antibodies in systemic vasculitis has been reported. The. aim of the study was to define the clinical associations of serum antiendothelial cell antibodies in patients with sudden sensorineural ...
Agostino, S   +6 more
core   +2 more sources

Leprosy with Atypical Skin Lesions Masquerading as Relapsing Polychondritis

open access: yesCase Reports in Infectious Diseases, 2016
Leprosy can present with a variety of clinical manifestations depending on the immune status of the individual. After dermatological and neurological involvement, rheumatic features specially various forms of arthritis are the third most common ...
Punit Pruthi   +5 more
doaj   +1 more source

Doc, Just Cut My Ears Off—A Case Report of Actinomyces in Bilateral Chronic Auricular Chondritis

open access: yesThe Laryngoscope, Volume 135, Issue 10, Page 3651-3653, October 2025.
Ear piercings can lead to infectious complications, commonly involving Staphylococcus aureus and Pseudomonas aeruginosa . This is the first documented case of bilateral chronic auricular chondritis caused by Actinomyces odontolyticus following cartilage piercings.
Niketna Vivek   +3 more
wiley   +1 more source

Relapsing Polychondritis that Recovers Rapidly with One-Dose Steroid: A Case Report

open access: yesİstanbul Medical Journal, 2015
Relapsing polychondritis is a rare, autoimmune, multisystemic disease that presents with episodic inflammatory process of the cartilages. We report a case of a 48-year-old woman who presented to our otolaryngology clinic with complaints of pain, eritema,
Abdurrahman Bozkurttan   +4 more
doaj   +1 more source

Beyond an Inflamed Ear

open access: yesActa Médica Portuguesa, 2014
Keywords: Ear Diseases; Ear, External; Polychondritis, Relapsing.
Cristina Ponte, Carla Macieira
doaj   +1 more source

Safety and Effectiveness of Combination Rituximab and Cyclophosphamide Therapy for Treating Pediatric Patients With Severe Manifestations of Rheumatic Disease

open access: yesACR Open Rheumatology, Volume 7, Issue 9, September 2025.
Objective Current practice guidelines recommend the use of either rituximab (RTX) or cyclophosphamide (CYC) for the treatment of severe manifestations of systemic vasculitis or connective tissue disease. Few studies have evaluated safety and efficacy outcomes of combination therapy with RTX and CYC.
Eileen Rife   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy